ProPhase Labs, Inc. (PRPH)
NASDAQ: PRPH · IEX Real-Time Price · USD
-0.28 (-5.25%)
May 24, 2024, 4:30 PM EDT - Market closed

Company Description

ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States.

It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.

It offers contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services.

In addition, the company involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations.

The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.

ProPhase Labs, Inc.
ProPhase Labs logo
Country United States
Founded 1989
IPO Date Jan 16, 1997
Industry Diagnostics & Research
Sector Healthcare
Employees 113
CEO Ted William Karkus

Contact Details

711 Stewart Ave, Suite 200, Garden City
New York, New York 11530
United States
Phone (215) 345-0919

Stock Details

Ticker Symbol PRPH
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000868278
CUSIP Number 74345W108
ISIN Number US74345W1080
Employer ID 23-2577138
SIC Code 2834

Key Executives

Name Position
Ted William Karkus Chairman and Chief Executive Officer
Jed A. Latkin Chief Operating Officer and Head of Finance Department
Robert A. Morse Jr. Controller, Principal Financial Officer and Principal Accounting Officer
Sergio Miralles Executive Vice President and Chief Information Officer
Jason Karkus President of Nebula Genomics
Kamal Obbad Senior Vice President and Director of Sales and Marketing - Nebula Genomics

Latest SEC Filings

Date Type Title
May 20, 2024 S-8 Securities to be offered to employees in employee benefit plans
May 15, 2024 DEF 14A Other definitive proxy statements
May 10, 2024 10-Q Quarterly Report
May 9, 2024 8-K/A [Amend] Current report
May 9, 2024 8-K Current Report
May 9, 2024 8-K/A [Amend] Current report
Apr 29, 2024 10-K/A [Amend] Annual report
Apr 18, 2024 8-K Current Report
Mar 29, 2024 10-K Annual Report
Mar 19, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership